文献速递糖尿病

扩大中低收入国家2型糖尿病患者新型药物可及性:成本效果与价格目标分析

Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-10-14

SGLT2抑制剂在减少并发症和满足价格目标方面尤其有前景。

要点

  • SGLT2抑制剂达到成本效果的中位价格目标为每年224美元。

核心结论

  • SGLT2抑制剂在减少糖尿病并发症和满足常见价格目标方面尤其有前景,尤其用于已确诊心血管或肾脏疾病者。
  • 研究结果与将SGLT2抑制剂纳入WHO基本药物目录的选择一致。

研究设计与样本

  • 微模拟涵盖心血管事件、心力衰竭、终末期肾病、视力丧失、压力感觉丧失、需医疗关注的低血糖及药物特异性副作用。

关键数值与推荐

  • 成本效果阈值定义为每避免一个残疾调整生命年低于3倍人均GDP。
  • 价格目标覆盖将磺脲类替换为SGLT2抑制剂或GLP-1受体激动剂、将人胰岛素替换为胰岛素类似物,以及不限血糖为心血管病、心衰或肾病患者加用SGLT2抑制剂或GLP-1受体激动剂。

临床怎么用

  • 在中低收入国家谈判新型降糖药纳入国家处方集时,可参考上述价格目标追求成本效果或净成本节约。
  • SGLT2抑制剂尤其应优先用于已确诊心血管或肾脏疾病的2型糖尿病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with type 2 diabetes in low-income and middle-income countries (LMICs), access to newer antidiabetic drugs (eg, sodium-glucose co-transporter-2 [SGLT2] inhibitors, glucagon-like peptide-1 [GLP-1] receptor agonists, and insulin analogues) could reduce the incidence of diabetes-related complications. We aimed to estimate price targets to pursue in negotiations for inclusion in national formularies given the addition of these novel agents to WHO's Essential Medicines List. METHODS: We incorporated individual-level, nationally representative survey data (2006-18) from 23 678 people with diabetes in 67 LMICs into a microsimulation of cardiovascular events, heart failure, end-stage renal disease, vision loss, pressure sensation loss, hypoglycaemia requiring medical attention, and drug-specific side-effects. We estimated price targets for incremental costs of switching to newer treatments to achieve cost-effectiveness (ie, <3-times gross domestic product per disability-adjusted life-year averted) or to achieve net cost-savings when including costs of averted complications. We compared switching to SGLT2 inhibitors or GLP-1 receptor agonists in place of sulfonylureas, or insulin analogues in place of human insulin, and also compared a glycaemia-agnostic pathways of adding SGLT2 inhibitors or GLP-1 receptor agonists to existing therapies for people with heart disease, heart failure, or kidney disease. FINDINGS: To achieve cost-effectiveness, SGLT2 inhibitors would need to have a median price of $224 per person per year (a 17·4% cost reduction; IQR $138-359, population-weighted across countries; mean price $257); GLP-1 receptor agonists $208 per person per year (98·3% reduction; $129-488; $240); and glargine insulin $20 per vial (31·0% reduction; $16-42; $28). To achieve net cost-savings, price targets would need to reduce by a further $9-10 to a median cost for SGLT2 inhibitors of $214 (21·4% reduction; $148-316; $245) and for GLP-1 receptor agonists to $199 per person per year (98·4% reduction; $138-294; $228); but insulin glargine remained around $20 per vial (32·4% reduction; $15-37; $26). Using SGLT2 inhibitors or GLP-1 receptor agonists in a glycaemia-agnostic pathway produced a 92% reduction (SGLT2 inhibitors) and 72% reduction (GLP-1 receptor agonists) in incremental cost-effectiveness ratios. INTERPRETATION: Among novel agents, SGLT2 inhibitors hold particular promise for reducing complications of diabetes and meeting common price targets, particularly when used among people with established cardiovascular or kidney disease. These findings are consistent with the choice to include SGLT2 inhibitors in the WHO Essential Medicines List. FUNDING: Clinton Health Access Initiative.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 2021. PMID: 34656210. doi:10.1016/S2213-8587(21)00240-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。